February 9, 2026
InnoCan Pharma Corporation
ISIN: CA45783P5085
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
Herzliya, Israel and Calgary, Alberta – February 09, 2026 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology...
Read more >>Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Herzliya, Israel and Calgary, AB – January 27, 2026 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now anticipates...
Read more >Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Herzliya, Israel and Calgary, AB – 2 January 2026– Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that it anticipates to list on NYSE American on or around January 7, 2026,...
Read more >Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Herzliya, Israel and Calgary, Alberta – November 27, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its financial consolidated results for the nine months ended September 30,...
Read more >Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
Herzliya, Israel and Calgary, Alberta – 24 November 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled “Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following...
Read more >Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model
Herzliya, Israel and Calgary, Alberta –20 November, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled “Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics and Safety Characteristics in Göttingen...
Read more >